822660 TAH001011772040620718822660Therapeutic Advances HematologyLE Franssen T Mutis reviewarticle2019 Review Ther Adv Hematol 2019 Vol 10 119 DOI 101177 httpsdoiorg1011772040620718822660 httpsdoiorg1011772040620718822660 2040620718822660 The Authors 2019 Article reuse guidelines sagepubcomjournals permissions Immunotherapy myeloma far come Laurens E Franssen Tuna Mutis Henk M Lokhorst Niels W C J van Donk Abstract The treatment multiple myeloma MM evolved substantially past decades leading significantly improved outcome MM patients The introduction highdose therapy especially autologous stem cell transplantation development new drugs immunomodulatory drugs IMiDs proteasome inhibitors contributed improvement survival However eventually MM patients relapse indicates need new agents novel treatment strategies Importantly longterm survival subset MM patients allogeneic stem cell transplantation illustrates potential immunotherapy MM allogeneic stem cell transplantation associated high rate treatmentrelated mortality Recently better insight immuneevasion mechanisms contribute tumor progression resulted development active welltolerated novel forms immunotherapy These immunotherapeutic agents monotherapy successfully combination established antiMM agents improve depth duration response preventing outgrowth resistant clones This review discuss mechanisms MM cells evade immune provide overview currently approved immunotherapeutic drugs IMiDs lenalidomide pomalidomide monoclonal antibodies target cell surface antigens present MM cell elotuzumab daratumumab novel immunotherapies chimeric antigen receptor Tcells bispecific antibodies checkpoint inhibitors currently clinical development MM Keywords multiple myeloma immunotherapy IMiDs bispecific antibodies CART cells checkpoint inhibitors monoclonal antibodies Received 24 September 2018 revised manuscript accepted 6 December 2018 Multiple myeloma Multiple myeloma MM malignant disease characterized clonal proliferation plasma cells bone marrow It disease elderly median age diagnosis 70 years 5 patients 40 years MM accounts 1 malignancies approxi mately 10 hematological malignancies The disease originates generally asympto matic precursor disease monoclonal gammopathy undetermined significance MGUS The pro cess transformation MGUS symptomatic MM associated sequential genetic microenvironmental changes1 Clinical charac teristics MM include osteolytic bone lesions hypercalcemia renal failure progressive bone marrow dysfunction anemia cyto penias12 The treatment MM undergone significant changes improvements recent years Next development proteasome inhibitors bortezomib carfilzomib ixazomib introduction immunomodula tory drugs IMiDs profound stimula tory effects immune direct antiMM activity thalidomide lenalido mide pomalidomide develop ment novel immunotherapies significantly improved outcome MM patients past decade34 However median sur vival currently 710 years eventually patients relapse This indicates need new antiMM agents potentiation currently Correspondence Niels W C J van Donk Department Hematology Amsterdam UMC Vrije Universiteit Amsterdam De Boelelaan 1117 1081 HV Amsterdam The Netherlands nvandedonkvumcnl Laurens E Franssen Tuna Mutis Henk M Lokhorst Department Hematology Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands journalssagepubcomhometah 1 Creative Commons Non Commercial CC BYNC This article distributed terms Creative Commons AttributionNonCommercial 40 License httpwwwcreativecommonsorglicensesbync40 permits noncommercial use reproduction distribution work permission provided original work attributed specified SAGE Open Access pages httpsussagepubcomenusnamopenaccessatsage Therapeutic Advances Hematology Therapeutic Advances Hematology 10 available therapies development alternative treatment combinations strategies Also increased insight resistance mechanisms current treatments lead new strategies prevent overcome treatment resistance This review aims provide outline mecha nisms immune evasion MM fol lowed discussion currently approved immunotherapy drugs novel immuno therapies stages clinical development MM results Immune evasion MM cells Immunotherapy induce potent clinical responses MM illustrated longterm survival subset patients allogeneic stem cell transplantation alloSCT suc cessful immunotherapeutic approaches described However like malignancies MM cells mechanisms escape immunemediated killing Insight mechanisms lead poten tial interventions improve immune therapy MM In following section number mech anisms immune evasion MM cells described Immune suppressor cells The studied immunosuppressive cell subsets induced MM cells reg ulatory Tcells Tregs myeloidderived sup pressor cells MDSCs Regulatory Tcells subset Tcells characterized expression CD4 CD25 forkhead box P3 FOXP3 low expression CD127 CD4CD25CD12 7lowFOXP3 Tregs naturally occurring generated thymus induced effec tor Tcells biologically important maintaining peripheral tolerance limiting autoimmune disease However suppress anticancer immune responses Tregs exert suppressive effect mechanisms They secrete suppressive cytokines transforming growth factor TGFβ IL10 capacity kill Bcells natu ral killer NK cells cytotoxic T lymphocytes CTLs secreting granzymeB In addition Tregs suppress function dendritic cells interaction CTLA4 lymphocyte activation gene 3 LAG3 ligands dendritic cells DCs Furthermore Tregs induce expression immunosuppressive enzyme indoleamine 23dioxygenase IDO DCs5 Several reports increased frequen cies Tregs peripheral blood MM patients610 Furthermore MM cells shown induce Tregs conventional Tcells ex vivo1112 However state Tregs dysfunctional similar levels Tregs MM patients compared healthy donors1316 These conflicting results explained 1 differences definition Treg phenotype 2 compartment Tregs measured peripheral blood versus bone marrow 3 disease status newly diag nosed versus relapsedrefractory MM In line idea MMinduced Treg expansion active immune suppression studies lower Treg numbers bone marrow peripheral blood associated MM patients1718 longterm Furthermore recent reports increased CD38 expression Tregs compared conventional Tcells alleviation Treginduced immune suppression MM achieved CD38targeting antibodies daratumumab isatuximab121319 survival function MDSCs heterogeneous immature popula tion CD11bCD33HLADRlow myeloid cells Two main subtypes MDSCs exist poly morphonuclear granulocytic MDSCs express ing CD15 CD66b monocytic MDSCs expressing CD14 addition pheno type mentioned MDSCs exert sup pressive distinct mechanisms They deplete essential amino acids like Larginine Lcysteine cause oxida tive stress production reactive oxygen spe cies reactive nitrogen species inhibiting Tcell function Furthermore interfere lymphocyte trafficking viability induce Tregs20 MDSCs increased frequencies peripheral blood bone marrow MM patients compared healthy donors2125 In addition MM cells shown induce MDSCs conversely MDSCs tributed disease progression MM24 These results indicate active immunosuppressive diseasepromoting role MDSCs MM In addition Tregs MDSCs regulatory Bcells Bregs described play role MM Bregs subset Bcells identified CD19CD24highCD38high cell surface pheno type regulate immune responses production antiinflammatory cytokine interleukin IL10 mechanisms26 2 journalssagepubcomhometah LE Franssen T Mutis et al In MM patients Bregs shown dis tinct population bone marrow microenvi ronment dependent presence MM cells capable suppressing antiMM cell antibodydependent cellular cytotoxicity ADCC NK cells27 Growth factors cytokines contribute immune suppression MM bone marrow microenvironment The MM microenvironment characterized production immunosuppressive cytokines A key cytokine pathogenesis disease progression MM IL6 produced bone marrow stromal cells BMSCs MM cells inhibit NK cell function28 Furthermore TGFβ production MM cells stromal cells osteoblasts inhibits Tcells NK cells DCs2930 A proliferation inducing ligand APRIL ligand Bcell maturation antigen BCMA pri marily secreted myeloid cells osteoclasts critical plasma cell growth survival APRIL shown upregulate genes involved immunosuppression MM cells TGFβ IL10 programmed death ligand 1 PDL1 abrogated antiAPRIL anti bodies31 APRIL binds transmembrane activator calcium modulator cyclophilin ligand interactor TACI TACI expressed plasma cells lower level compared BCMA TACI expressed significantly higher levels Tregs compared conven tional Tcells APRIL shown promote Treg viability inhibiting apoptosis abrogated addition antiAPRIL antiTACI antibodies32 APRIL enhanced Tregmediated inhibition conventional Tcell proliferation increased induction Tregs MM cells32 Coinhibitory molecules Activated Tcells express coinhibitory molecules immunecheckpoint molecules cytotoxic T lymphocyte associated antigen4 CTLA4 programmed death1 PD1 Binding receptors corresponding ligands CD8086 CTLA4 PDligand12 PDL1PDL2 PD1 antigenpresenting cells APCs leads controlled inhibition activated Tcells confers protection immunemediated diseases However soon discovery natural protection mecha nisms appeared tumor cells effectively exploited feedback loops upregulating expression coinhibitory receptors33 A number coinhibitory molecules described upregulated MM PDL1 expression increased MM cells partly explained interferonγ produced BMSCs shown induce apoptosis anergy myelomaspecific Tcells3436 In addi tion PDL1 expression MM cells intrinsic effects It shown PDL1positive MM cell lines proliferation advantage increased levels antiapoptotic proteins decreased sensitivity dexamethasone mel phalan3637 Besides PDL1 MM cells express increased levels carcinoembryonic antigen related cell adhesion molecules CEACAMs CEACAM6 shown inhibit antiMM Tcell activity completely abrogated antibodies38 antiCEACAM6 Furthermore higher expression trans membrane glycoprotein CD200 MM cells diagnosis correlates decreased eventfree survival highdose therapy autologous transplantation possibly inhibition Tcell activity binding ligand CD200R Tcells39 On Tcell increased expression PD1 CTLA4 observed bone mar rowlocalized Tcells MM patients indicating exhausted phenotype reversed blocking receptors therapeutic anti bodies targeting PD1 PDL140 Cell adhesionmediated immune resistance BMSCs vascular endothelial cells MM patients suppress CTLs NK cell mediated killing MM cells regulating anti proapoptotic pathways MM cells4142 This immune resistance shown induced cellcell adhesion decreased significantly adhesion abrogated Upon cellcell adhesion downregulation Fas upregu lation survivin Mcl1 observed Using small molecule YM155 survivin leading Mcl1 suppressed increased MM cell lysis CTLs4142 Other mechanisms immune suppression Expression indoleamine 23dioxygenase IDO MM cells catalyzes metabolization tryptophan amino acid essential cell growth functioning immune cells journalssagepubcomhometah 3 Therapeutic Advances Hematology 10 Figure 1 Schematic overview immunotherapeutic options multiple myeloma Ab antibody alloSCT allogeneic stem cell transplantation CAR Tcells chimeric antigen receptor Tcells DLI donor lymphocyte infusion IMiDs immunomodulatory drugs NK natural killer PD1 programmed death receptor 1 PDL1 programmed death ligand 1 SLAMF7 signaling lymphocytic activation molecule family 7 leading immune suppression In addition leads recruitment Tregs43 Increased production soluble major histocompatibility complex class Irelated chain A sMICA MM leads impaired Tcell NK cell function44 In addition studies shown defective antigenprocessing machinery human leuko cyte antigen HLA class I downregulation MM cells This leads decreased recognition tumor cells CD8 Tcells4546 Immunotherapy MM The general principle cancer immunotherapy administer activate immune cells order gain targeted approach cancer reducing target effects This approach contrast traditional chemother apeutic treatment modalities generally nonspecific cytotoxic therapies substantial effects In MM immunotherapies currently approved treatment MM immunotherapeutic approaches currently focus active investigations4749 Here discuss number immunotherapeutic strategies currently outside clinical trials investigated MM patients Figure 1 Allogeneic stem cell transplantation AlloSCT considered immu notherapies applied MM In alloSCT stem cells donor administered patient In TRM pretreated radiation chemother apy chemotherapy Tcells donor coadministered stem cells recognize eliminate tumor cells resulting called graftversustumor effect GVT Unfortunately donor Tcells recognize normal tissue foreign causing detrimental graftver sushostdisease GVHD major cause treat mentrelated mortality HLAmatched setting GVT effect mainly mediated recognition minor histocom patibility antigens mHags presented malig nant cells50 These transplantation antigens peptides derived polymorphic regions intracellular proteins Upon binding HLA mol ecules presented Tcells donor Variations intracellular proteins exist donor recipient evolutionary occurrence instance single nucleotide polymorphisms SNPs coding regions genome creating peptides dif fer amino acid sequence Therefore mHags foreign antigens donor induce potent alloimmune Tcell responses setting HLAmatched transplantation Figure 25152 The tissue distribution mHags determines contribution GVT GVHD effects mHags expressed exclusively hemat opoietic cells dominant role benefi cial GVT effect mHags broad tissue expression cause GVT GVHD In 4 journalssagepubcomhometah LE Franssen T Mutis et al Figure 2 Schematic overview mHag presentation recipient cells leading activation donor Tcells Genetic polymorphisms leading differences amino acids rise differential presentation mHags cells recipient right cells donor present antigen different antigen mHag minor histocompatibility antigen MHC major histocompatibility complex SNP single nucleotide polymorphism TCR Tcell receptor addition tissue distribution population frequency mHag important mHags low high population frequency relevant immunotherapeutic point view chances mismatch donor recipient low The chance mismatch actually maximum mHag population frequency 505354 The existence GVT effect MM clearly demonstrated studies evaluating donor lymphocyte infusions treatment relapsed MM alloSCT5557 However allo transplantation potentially induce powerful GVT effect occur autologous transplantation autoSCT studies comparing tandem autoSCT versus autoSCT followed alloSCT upfront setting shown conflicting results5869 Several studies eventfree survival overall survival OS benefit alloSCT58606167 difference survival7075 Some studies suggest alloSCT overcome unfavora ble prognosis patients adverse cytogenetic aberrations5976 difference outcome highrisk patients MM dou ble autoSCT compared tandem auto alloSCT6669 However majority studies performed introduction proteasome inhibitors immunomodulatory journalssagepubcomhometah 5 Therapeutic Advances Hematology 10 agents definition highrisk cytoge netics similar currently This high rate TRM 1020 led reduced application alloSCT upfront therapy MM Patients early relapse 18 months autoSCT poor prognosis alloSCT consid ered patients successful induction therapy preferentially context clinical trial7780 However outcome allo SCT patients established Key improvement alloSCT MM patients development toxic conditioning regiments improvement sustained GVT responses reduction better treatment GVHD Postallo immunotherapy modalities donor lympho cyte infusions DC vaccinations NK cell ther apy subject investigation8185 It expected application alloSCT MM decrease introduction active toxic immunotherapies Immunomodulatory drugs Although currently named IMiDs broadly applied treatment MM IMiDs initially designed thalidomide firstinclass IMiD developed seda tive antiemetic drug IMiDs multiple mech anisms action including immunestimulatory antiangiogenic properties direct antiMM activity86 IMiDs bind Cereblon substrate receptor ubiquitin E3ligase complex CRL4CRBN include damagespe cific DNA binding protein DDB1 cullin 4A Cul4 RING finger protein 1 ROC18790 After binding specific substrate proteins IKZF1 Ikaros IKZF3 Aiolos recruited E3 ligase targeted ubiquitination subsequent proteasomal degradation The degradation Ikaros Aiolos followed downregulation interferon regulatory factor 4 IRF4 cMyc leading growth inhibition apoptosis MM cells Figure 3 Ikaros Aiolos shown act repres sors IL2 transcription CD4 CD8 Tcells889194 This explains immune cells IMiDinduced Cereblondependent degra dation Ikaros Aiolos results increased IL2 production enhancing pro duction cytokines interferon IFNγ IL4 IL6 IL10 IL13 granulocytemac rophage colonystimulating factor GMCSF94 This leads activation Tcells NK cells9596 In addition effect IMiDs Figure 3 The ubiquitin E3ligase complex CRL4CRBN causing ubiquitination IKZF1 IKZF3 IMiD binding leading proteasomal degradation subsequent immunomodulatory MM cytotoxic effects CRBN Cereblon CUL4 cullin 4A DDB1 damagespecific DNA binding protein IKZF Ikaros family zinc finger protein IL2 interleukin 2 IRF4 interferon regulatory factor 4 MM multiple myeloma ROC1 RIN G finger protein 1 TNF tumor necrosis factor Tcells NK cells lenalidomide shown increase expression DC matura tion markers CD86 HLADR CD209 treatment DCs lenalidomide vitro enhanced ability stimulate autologous Tcells9798 In addition lenalidomide abrogated inhibitory effect mesenchymal stromal cells DC maturation vitro downregulating Cereblon substrate protein CK1α97 After recognition teratogenic effects thalidomide drug withdrawn market 1961 In 1990 antimyeloma effects 6 journalssagepubcomhometah thalidomide observed administration drug patients endstage MM led rapid increase clinical trials inves tigating thalidomide MM99 In order improve activity reduce toxicity new IMiDs designed evaluated MM Lenalidomide secondgeneration IMiD approved 2006 treatment relapsedrefractory myeloma combination dexamethasone This combination showed sig nificantly better response rate compared tha lidomidedexamethasone showed activity patients previously treated thalido mide100101 Importantly lenalidomide induced significantly neuropathy compared thalidomide The thirdgeneration IMiD poma lidomide approved treatment relapsed refractory MM patients received prior lines therapy including lenalidomide bortezomib Pomalidomide activity lenalidomiderefractory patients overall response rates ORRs 34 patients102 In relapsedrefractory setting IMiDs treatment combinations77 Interestingly moment new IMiDs CC220 investigated phase I clinical trials extensively pretreated MM patients Because IMiDs showed marked antiMM activity relapsedrefractory MM evalu ated newly diagnosed MM patients At moment lenalidomide combination dexa methasone standards care newly diagnosed MM patients eligible transplant77 Furthermore transplant eligi ble patients triplets bortezomibdexametha sone IMiD lenalidomide VRD thalidomide VTD frequently induc tion regiments prior highdose therapy autoSCT Lenalidomide improves progres sionfree survival PFS OS given maintenance therapy autoSCT newly diagnosed MM patients approved mainte nance drug setting103 Monoclonal antibodies therapeutic effect anti The substantial CD20 monoclonal antibodies treatment Bcell lymphoma indicates potential mono clonal antibodies anticancer treatment104 In contrast genetic heterogeneity MM sequential genetic changes disease progressing immune phenotype homo geneous Furthermore different mode action immunotherapeutic treatment strategies LE Franssen T Mutis et al makes cross resistance antiMM drugs likely Identification proteins highly stably expressed MM cells different disease stages attractive targets therapeutic monoclonal antibodies The antibody targets signaling lymphocytic activation molecule F7 SLAMF7 CD38 particular MM Elotuzumab humanized immunoglobulin IgG1 monoclonal antibody targets SLAMF7 SLAMF7 highly expressed plasma cells NK cells lesser extent subset activated Tcells Bcells Elotuzumab shown act primarily ADCC singleagent activity extensively pretreated MM105 Preclinical studies showed lenalidomide potentiates elotu zumabmediated ADCC improving NK cell activity106 In randomized phase III trial elotu zumab Elo lenalidomide dexamethasone Rd compared Rd relapsed refrac tory 94 lenalidomidenaïve MM patients ORRs 79 versus 66 p 0001 median PFS 194 months versus 149 months respectively hazard ratio 070 p 0001107 The 1 2 3year OS rates EloRD 91 73 60 83 69 53 Rdtreated patients respectively108 Most common grade 34 adverse events neutro penia thrombocytopenia Infusionrelated reactions IRRs occurred 10 patients Elotuzumab combined borte zomib dexamethasone randomized phase II trial compared bortezomibdexa methasone resulting superior PFS hazard ratio 072 median PFS 97 versus 69 months109 The second important antibody target MM CD38 CD38 highly expressed plasma cells followed NK cells subpopulations Tcells Bcells Furthermore expressed myeloid cells erythrocytes platelets Several CD38targeting antibodies developed daratumumab isatuximab MOR202 These antibodies multiple mechanisms action including cytotoxicity complementdependent CDC ADCC antibodydependent cellular phagocytosis110 Interestingly daratumumab reduces CD38 immune suppressor cell popula tions Tregs Bregs MDSCs potentially leading better antitumor immune response19 Daratumumab potent singleagent activity shown GEN501 Sirius trials pub lished 2015 2016111112 Pooled analysis studies showed ORR 311 PFS journalssagepubcomhometah 7 Therapeutic Advances Hematology 10 4 months OS 201 months relapsed refractory MM patients median prior lines therapy113 Daratumumab toler ated IRRs observed 48 patients consisted chills nausea respiratory condi tions 27 patients grade 3 IRRs113 The main hematological adverse events anemia thrombocytopenia neutropenia Most common nonhematological adverse events fatigue nausea pain Based high activity daratumumab MM CD38 targeting antibodies developed including MOR202 isatuximab comparable singleagent activity advanced MM114115 Similar elotuzumab combining daratumumab lenalidomide increased NK cellmediated ADCC preclinical studies led clinical trials combining antiCD38 antibodies IMiD showing significantly improved outcome combination compared antiCD38 antibody monotherapy In POLLUX trial Rd compared daratumumabRd patients prior therapy lenalido miderefractory disease PFS 12 months 601 Rd versus 832 daratumumabRd In addition complete response rates measura ble residual disease MRD negativity signifi cantly higher daratumumabRd116 Similarly combining daratumumab bortezomib dexamethasone resulted significantly higher response rate depth response PFS MM patients prior therapy bortezomibrefractory disease117 Others investi gated phase Ib study combination dara tumumab plus pomalidomidedexamethasone relapsedrefractory MM patients 89 lenalido miderefractory 71 bortezomibrefractory 30 carfilzomibrefractory ORRs 60 median PFS OS 88 months 175 months respectively118 A recent phase III study describes use daratumumab newly diagnosed trans plant ineligible patients comparing bortezomib melphalan prednisone VMP VMP plus daratumumab VMP combined daratumumab increased ORR rates complete significantly improved PFS119 response CR rates Daratumumab currently approved European Medicines Agency EMA United States Food Drug Administration US FDA monother apy relapsedrefractory myeloma combi nation Rd bortezomibdexamethasone VD patients prior line ther apy The US FDA approved daratumumab combination pomalidomidedexamethasone PD treatment MM patients received prior therapies including lena lidomide proteasome inhibitor In addition US FDA recently EMA approved daratumumab plus VMP newly diagnosed patients ineligible autoSCT In addition CD38 SLAMF7 BCMA interesting target MM therapy BCMA member tumor necrosis factor superfamily expressed Bcells normal plasma cells highly expressed MM cells Preclinical studies shown anti BCMA antibody conjugated microtubule disrupting agent monomethyl auristatinF anti bodydrug conjugate named GSK2857916 spe cifically inhibits MM cell activity induces effective ADCC allogeneic autolo gous MM cells120 This led clinical phase II study currently ongoing investigates compound heavily pretreated relapsed refractory MM patients Preliminary results median 66 months ORR 60 median PFS 79 months121 Chimeric antigen receptor Tcells In chimeric antigen receptor CAR antigen recognition monoclonal antibody com bined Tcell receptor domains costimulatory domains The CAR gene introduced Tcells viral transduction This generates cells directly recognize tumor antigens followed activation cytotoxic machinery Tcell causing kill target cells122 The advantages CAR Tcells HLAindependent mode action com pared unmodified Tcells efficient kill compared antibodies ADCC The expansion activation CAR Tcells patients lead called cytokine release syndrome This potentially fatal clinical syndrome caused striking release pro inflammatory cytokines characterized fever dyspnea hypotension lead shock multiorgan failure However use antiIL6 antibody tocilizumab corticos teroids effective majority patients Successful clinical results obtained CD19 targeting CAR Tcells Bcell malignancies123124 These results led development CAR Tcells targets In MM use antiBCMA CAR Tcells currently investigated studies 8 journalssagepubcomhometah LE Franssen T Mutis et al s c t u e p r e h T 1 7 1 H R A C M o n u J K S M d n e g e L M 8 3 B R A C L d r b e u l B 1 2 1 2 b b s t r v o N n n e P U I C N 7 2 3 0 7 0 3 0 T C N 1 3 1 s e u g e l l o c 9 5 6 0 9 0 3 0 T C N 9 2 9 8 5 6 2 0 T C N 7 6 1 6 4 5 2 0 T C N d n h t m S 0 3 1 s e u g e l l o c d n g n h Z 9 2 1 6 2 1 s e u g e l l o c d n e R j 7 2 1 s e u g e l l o c d n n e h o C 7 6 9 5 1 2 2 0 T C N 5 2 1 s e u g e l l o c d n o n d u r B v o g s l r t l c n l C e c n e r e f e R r e f t n e d M M n s l l e c T R A C d e t e g r t A M C B g n t u l v e s l r t f o s c t s r e t c r h C 1 e l b T s e d o b t n n h c y v e h m l f o s t n e m g r f n m u h v F c s e l b r v c f c e p s B e n r u m v F c s n m u h v F c s e n r u m v F c s B B 1 4 ζ 3 D C B B 1 4 ζ 3 D C B B 1 4 ζ 3 D C B B 1 4 ζ 3 D C 8 2 D C ζ 3 D C n m o d g n d n b g A s n m o d g n l n g S y C u l F r o y C t R F G E s e Y 6 5 7 7 6 6 0 1 7 3 1 2 7 e s o d n e M 0 8 s t n e t p e l b u l v e 5 0 s t n e t p e l b u l v e 5 6 0 1 4 e s o d n d e M 1 4 t r o h o c 6 0 1 0 0 8 0 5 R C s 3 6 7 4 6 3 n 6 0 1 0 0 8 0 5 1 0 0 1 1 8 6 3 n s l l e c 6 0 1 0 0 8 0 5 1 7 0 1 5 1 y C 8 0 1 5 1 y C 2 t r o h o C 3 t r o h o C 8 0 1 5 1 1 t r o h o C 4 4 1 t r o h o C 0 2 2 t r o h o C 0 6 3 t r o h o C 1 1 1 t r o h o C 0 2 t r o h o C 0 1 3 t r o h o C 6 0 1 9 g k e s o d T R A C 1 8 3 1 R P R C A N e s o d 6 1 4 1 t 4 1 4 t p 7 1 l e D 3 5 P T r o p 7 1 l e d 1 7 6 9 n o s n p x e 8 3 t r o h o c n o t l c s e n o t t u m 1 3 8 3 p 7 1 l e d s c t e n e g o t y c k s r h g H e n o N y C s e Y 5 3 4 t r o h o c n o s n p x e s t o n d e r u q e r e s h p n o t l c s e e s o d n I e n o N y C u l F 3 4 7 e n o N y C o N 4 2 7 e n o N y C u l F n o t e l p e d o h p m y L e n e g e d c u S s e Y n o s s e r p x e A M C B d e r u q e r 6 2 0 1 s t n e t p f o r e b m u N d e d u l c n r o r p f o r e b m u N n d e m s e p r e h t r o t c F h t w o r G l l e h t o d n E d e t c n u r t t R F G E e d m h p s o h p o l c y c y C e m o r d n y s e s e l e r e n k o t y c S R C e s n o p s e r e t e l p m o c R C r o t p e c e r n e g t n c r e m h c R A C n e g t n n o t r u t m l l e c B A M C B n e g t n g A e s n o p s e r e t e l p m o c t n e g n r t s R C s t n e m g r f e l b r v n h c e l g n s v F c s e s n o p s e r l t r p R P r e f t n e d v o g s l r T l c n l C T C N e t u t t s n I r e c n C l n o t N I C N e l b l v t o n A N e n b r d u l f u l F r o t p e c e R 0 5 3 8 3 6 3 8 1 8 s e d r g l l S R C journalssagepubcomhometah 9 Therapeutic Advances Hematology 10 Table 1125131 In studies heavily pre treated relapsedrefractory MM patients treated different doses antiBCMA CAR Tcells short course leukocytedepleting chemotherapy High response rates observed partial response PR ranging 77100 including patients achieving stringent CR Cytokinerelease syndrome occurred frequently grades ranging 5083 manageable125131 Another study investigated CAR Tcells targeting kappa light chain seven MM patients132 No objective responses observed treatment CAR Tcells lead stable disease ranging 217 months significant toxicities132 Several preclinical CAR T studies shown promising results MM antigens including CD38 CD44v6 SLAMF7 form ing rationale new clinical trials81133135 Bispecific antibodies Despite promising clinical results CAR Tcells particularly CD19 targeting CAR Tcells Bcell malignancies production requires use autologous cells considerably timeconsuming Bispecific antibodies BsAbs contain antigenrecognition domains One designed recognize CD3 expressed Tcells tar geting tumor antigen This technique enables bringing Tcells proximity tumor cells caus ing Tcell proliferation tumor cell lysis BsAbs generated large quantities stored use creating shelf prod uct Bispecific Tcell engagers BiTEs type BsAbs consisting singlechain variable fragments different antibodies A potential advantage BiTEs shorter half life compared larger BsAb constructs management toxic effects simply halt ing infusion136 In line CAR Tcell stud ies successful clinical results obtained CD3CD19 BiTE blinatumomab target ing CD19 positive ALL137138 relapsedrefractory diffuse large Bcell lymphoma DLBCL types NHL139140 In preclinical MM studies antigens investigated therapeutic target BsAbs including BCMA CD38 CD138 Fc receptor like 5 Fcrl5141142 Based promising preclinical results clinical trials BiTEs BsAbs ongoing MM The mode action BsAbs requires wellfunctioning autologous Tcells However MM characterized defective immune potentially limiting effec tiveness Furthermore regulatory Tcells express CD3 activated use BsAbs decreasing antitumor immune responses143 Immunecheckpoint inhibition The development antibodies blocking coinhib itory receptors checkpoint inhibitors caused major shift forward cancer immunotherapy Successful results checkpoint inhibitors relapsedrefractory Hodgkins lymphoma144145 led studies hematological malignancies including MM An increased expression PDL1 malignant plasma cells observed MM patients elevated PD1 expres sion Tcells NK cells3540146147 Despite findings monotherapy PD1 inhibi tor nivolumab clinical activity148 Nevertheless phase I study combination pembrolizumab antiPD1 antibody lenalid omide dexamethasone ORR 50 heavily pretreated relapsedrefractory MM patients149 ORR increasing 60 lenalidomide replaced pomalidomide phase II study150 However present studies investigating combination IMiDs PD1 PDL1 inhibitors clinical hold increased number deaths phase III stud ies investigating combination pembroli zumab pomalidomide relapsedrefractory KEYNOTE 183 study lenalidomide newly diagnosed MM KEYNOTE 185 study However based preclinical studies showing synergy PD1PDL1 inhibitors anti bodies targeting MM cell surface antigens clinical trials evaluating PD1PDL1 inhibitors antiMM agents daratumumab ongo ing ClinicalTrialsgov identifiers NCT01592370 NCT03184194151 Dendritic cell vaccination The ultimate goal DC vaccination strategies vivo induction stimulation tumor spe cific Tcell immunity cancer cells anti gendependent fashion patients experience antitumor effect develop longterm protection possible relapse disease DCs professional APCs capable efficiently stimulating naïve Tcells build antitumor response152 DCbased immunotherapy studied wide range malignancies shown safe153 In MM different 10 journalssagepubcomhometah LE Franssen T Mutis et al strategies studied including autologous DCs pulsed idiotype autologous DCs fused MM cells autologous DCs loaded myelomaassociated antigen mRNA MAGE3 BCMA survivin154157 Although use idiotype pulsed DCs DCs loaded mye lomaassociated antigen mRNA resulted induction antigen specific Tcells subset patients clinical responses disappointing However promising results observed DCMM fusion vaccines In phase II clini cal study use DCMM fusion vaccines autoSCT shown induce antiMM CD4 CD8 Tcells conversion PR CR following vaccination 24 patients154 This led currently ongoing threearm multicenter phase II randomized clinical trial ran domizing patients upfront autoSCT 1 vaccination DCMM cell fusion vaccine plus GMCSF plus lenalidomide maintenance 2 lenalidomide maintenance GMCSF 3 lenalidomide maintenance ClinicalTrialsgov identifier NCT02728102 DCs inter est following alloSCT shown GVT effect depends presence host DCs capable presenting host antigens158160 However alloSCT results rapid replacement host DCs donor DCs hamper alloreactivity donor lymphocytes161 Therefore GVT effect theoretically boosted administration DCs capable presenting host antigens We published phase III trials investigating combination donor lymphocyte infusions combined DCs loaded mHag alloSCT162163 In trials able induction mHagspecific Tcells vaccination However clinical responses dis appointing indicating need improvement current vaccination strategy Future perspectives It clear immunotherapy way MM adding significant improvement survival patients Challenges lie ahead timing immunotherapeutic strategies disease course While studies formed relapsedrefractory setting likely patients benefit immunother apy applied earlier time point Indeed dara tumumab combined VMP approved newly diagnosed patients successful results ALCYONE study119 However application immunotherapy earlier disease course consideration potential toxicities treatments CAR Tcells addition costs Secondly line optimal timing optimal sequence increasing number effective immune therapies currently unknown Thirdly optimal combination treatments targeting myeloma myelomaassociated immunosuppression sought potentiate therapies Despite chal lenges come far Funding This research received specific grant funding agency public commercial forprofit sectors Conflict statement NvdD research support Celgene Janssen Pharmaceuticals Novartis BMS AMGEN advisory boards Celgene Janssen Pharmaceu ticals Novartis BMS AMGEN Takeda Bayer Servier HML Research support honoraria Celgene Janssen Pharmaceuticals The authors declare conflicts work ORCID iD Niels W C J van Donk org0000000274452603 httpsorcid References 1 Palumbo A Anderson K Multiple myeloma N Engl J Med 2011 364 10461060 2 Kyle RA Rajkumar SV Multiple myeloma N Engl J Med 2004 351 18601873 3 Kumar SK Dispenzieri A Fraser R et al Early relapse autologous hematopoietic cell transplantation remains poor prognostic factor multiple myeloma outcomes improved time Leukemia 2018 324 986995 4 Kumar SK Dispenzieri A Lacy MQ et al Continued improvement survival multiple myeloma changes early mortality outcomes older patients Leukemia 2014 28 11221128 5 Vignali DA Collison LW Workman CJ How regulatory T cells work Nat Rev Immunol 2008 8 523532 6 Giannopoulos K Kaminska W Hus I et al The frequency T regulatory cells modulates journalssagepubcomhometah 11 Therapeutic Advances Hematology 10 survival multiple myeloma patients detailed characterisation immune status multiple myeloma Br J Cancer 2012 106 546552 7 Muthu Raja KR Rihova L Zahradova L et al Increased T regulatory cells associated adverse clinical features predict progression multiple myeloma PLoS One 2012 7 e47077 longterm disease control multidimensional flow cytometry Haematologica 2013 98 7986 18 Bryant C Suen H Brown R et al Longterm survival multiple myeloma associated distinct immunological profile includes proliferative cytotoxic Tcell clones favourable TregTh17 balance Blood Cancer J 2013 3 e148 19 Krejcik J Casneuf T Nijhof IS et al 8 Favaloro J Brown R Aklilu E et al Myeloma skews regulatory T proinflammatory T helper 17 cell balance favor suppressive state Leuk Lymphoma 2014 55 10901098 Daratumumab depletes CD38 immune regulatory cells promotes Tcell expansion skews Tcell repertoire multiple myeloma Blood 2016 128 384394 9 Feyler S von LilienfeldToal M Jarmin S 20 Gabrilovich DI OstrandRosenberg S et al et al CD4CD25FoxP3 regulatory T cells increased whilst CD3CD4 CD8alphabetaTCR double negative T cells decreased peripheral blood patients multiple myeloma correlates disease burden Br J Haematol 2009 144 686695 10 Beyer M Kochanek M Giese T et al In vivo peripheral expansion naive CD4CD25high FoxP3 regulatory T cells patients multiple myeloma Blood 2006 107 3940 3949 11 Tai YT Anderson KC Targeting CD38 alleviates tumorinduced immunosuppression Oncotarget 2017 8 112166112167 12 Feng X Zhang L Acharya C et al Targeting CD38 suppresses induction function T regulatory cells mitigate immunosuppression multiple myeloma Clin Cancer Res 2017 23 42904300 13 Gupta R Ganeshan P Hakim M et al Significantly reduced regulatory T cell population patients untreated multiple myeloma Leuk Res 2011 35 874878 14 Foglietta M Castella B Mariani S et al The bone marrow myeloma patients steadily inhabited normalsized pool functional regulatory T cells irrespective disease status Haematologica 2014 99 16051610 Coordinated regulation myeloid cells tumours Nat Rev Immunol 2012 12 253268 21 Wang Z Zhang L Wang H et al Tumor induced CD14HLADRlow myeloid derived suppressor cells correlate tumor progression outcome therapy multiple myeloma patients Cancer Immunol Immunother 2015 64 389399 22 Favaloro J Liyadipitiya T Brown R et al Myeloid derived suppressor cells numerically functionally phenotypically different patients multiple myeloma Leuk Lymphoma 2014 5512 2893900 23 Ramachandran IR Martner A Pisklakova A et al Myeloidderived suppressor cells regulate growth multiple myeloma inhibiting T cells bone marrow J Immunol 2013 190 38153823 24 Görgün GT Whitehill G Anderson JL et al Tumorpromoting immunesuppressive myeloidderived suppressor cells multiple myeloma microenvironment humans Blood 2013 121 29752987 25 Brimnes MK Vangsted J Knudsen LM et al Increased level CD4FOXP3 regulatory T cells CD14HLADR low myeloidderived suppressor cells decreased level dendritic cells patients multiple myeloma Scand J Immunol 2010 72 540547 15 Prabhala RH Neri P Bae JE et al 26 Rosser EC Mauri C Regulatory B cells Dysfunctional T regulatory cells multiple myeloma Blood 2006 107 301304 origin phenotype function Immunity 2015 42 607612 16 Darena G Rossi G Laurenti L et al 27 Zhang L Tai Y Ho M et al Regulatory Circulating regulatory Tcells monoclonal gammopathies uncertain significance multiple myeloma search role J Immunol Res 2016 2016 18 B cellmyeloma cell interaction confers immunosuppression promotes survival bone marrow milieu Blood Cancer J 20177 e547 17 Pessoa Magalhaes RJ Vidriales MB Paiva B et al Analysis immune multiple myeloma patients achieving 28 Noonan K Borrello I The immune microenvironment myeloma Cancer Microenviron 20114 313323 12 journalssagepubcomhometah LE Franssen T Mutis et al 29 Wrzesinski SH Wan YY Flavell RA 41 Haart SJ van Donk NWCJ Transforming growth factorβ immune response implications anticancer therapy Clin Cancer Res 2007 13 52625270 30 Cook G Campbell JD Carr CE et al Transforming growth factor beta multiple myeloma cells inhibits proliferation IL2 responsiveness T lymphocytes J Leukoc Biol 1999 66 981988 31 Tai YT Acharya C An G et al APRIL BCMA promote human multiple myeloma growth immunosuppression bone marrow microenvironment Blood 2016 127 32253236 32 Tai YT Lin L Xing L et al APRIL signaling TACI mediates immunosuppression T regulatory cells multiple myeloma therapeutic implications Leukemia 2018 Epub ahead print 33 Norde WJ Hobo W van der Voort R et al Review article Coinhibitory molecules hematologic malignancies targets therapeutic intervention Blood 2012 120 728736 34 Liu J Hamrouni A Wolowiec D et al Plasma cells multiple myeloma patients express B7H1 PDL1 increase expression stimulation IFNgamma TLR ligands MyD88 TRAF6 MEK dependent pathway Blood 2007 110 296304 35 Atanackovic D Luetkens T Kröger N Coinhibitory molecule PD1 potential target immunotherapy multiple myeloma Leukemia 2014 28 9931000 Minnema MC et al Accessory cells microenvironment protect multiple myeloma Tcell cytotoxicity cell adhesion mediated immune resistance Clin Cancer Res 2013 19 55915601 42 Haart SJ Holthof L Noort WA et al Sepantronium bromide YM155 improves daratumumabmediated cellular lysis multiple myeloma cells abrogation bone marrow stromal cellinduced resistance Haematologica 2016 101 e339e342 43 Bonanno G Mariotti A Procoli A et al Indoleamine 23dioxygenase 1 IDO1 activity correlates immune abnormalities multiple myeloma J Transl Med 2012 10 117 44 Rebmann V Schütt P Brandhorst D et al Soluble MICA independent prognostic factor overall survival progression free survival multiple myeloma patients Clin Immunol 2007 123 114120 45 Klippel ZK Chou J Towlerton AM et al Immune escape NYESO1specific Tcell therapy loss heterozygosity MHC Gene Ther 2014 21 337342 46 Racanelli V Leone P Frassanito MA et al Alterations antigen processingpresenting machinery transformed plasma cells associated reduced recognition CD8 T cells characterize progression MGUS multiple myeloma Blood 2018 115 11851194 36 Tamura H Ishibashi M Yamashita T et al 47 Rasche L Weinhold N Morgan GJ et al Marrow stromal cells induce B7H1 expression myeloma cells generating aggressive characteristics multiple myeloma Leukemia 2013 27 464472 37 Ishibashi M Tamura H Sunakawa M et al Myeloma drug resistance induced binding myeloma B7H1 PDL1 PD1 Cancer Immunol Res 2016 4 779788 38 WitzensHarig M Hose D Jünger S et al Tumor cells multiple myeloma patients inhibit myelomareactive T cells carcinoembryonicantigenrelated cell adhesion molecule6 Blood 2013 121 44934503 39 Moreaux J Hose D Reme T et al CD200 new prognostic factor multiple myeloma Blood 2014 108 41944198 40 ZelleRieser C Thangavadivel S Biedermann Immunologic approaches treatment multiple myeloma Cancer Treat Rev 2017 55 190199 48 Roeven MWH Hobo W Schaap N et al Immunotherapeutic approaches treat multiple myeloma Hum Vaccin Immunother 201410 896910 49 Kumar SK Anderson KC Immune therapies multiple myeloma Clin Cancer Res 2016 22 54535460 50 Spierings E Kim YH Hendriks M et al Multicenter analyses demonstrate significant clinical effects minor Histocompatibility Antigens GvHD GvL HLA matched related unrelated Hematopoietic stem cell transplantation Biol Blood Marrow Transplant 2013 19 12441253 R et al T cells multiple myeloma display features exhaustion senescence tumor site J Hematol Oncol 2016 9 116 51 Goulmy E Minor Histocompatibility antigens transplantation problems therapy cancer Hum Immunol 2006 67 433438 journalssagepubcomhometah 13 Therapeutic Advances Hematology 10 52 Goulmy E Minor histocompatibility antigens allo target molecules tumorspecific immunotherapy Cancer J 2004 10 17 53 van Loenen MM Boer R Hagedoorn RS et al Optimization HA1specific Tcell receptor gene therapy hematologic malignancies Haematologica 2011 96 477481 54 Bueger M Bakker A Van Rood JJ et al Tissue distribution human minor histocompatibility antigens Ubiquitous versus restricted tissue distribution indicates heterogeneity human cytotoxic T lymphocytedefined nonMHC antigens J Immunol 1992 149 17881794 55 Lokhorst HM Wu K Verdonck LF et al The occurrence graftversushost disease major predictive factor response donor lymphocyte infusions multiple myeloma Blood 2004 103 43624364 56 Verdonck LF Lokhorst HM Dekker AW et al Graftversusmyeloma effect cases Lancet 1996 347 800801 57 Tricot G Vesole DH Jagannath S et al Graft versusmyeloma effect proof principle Blood 1996 87 11961198 58 Giaccone L Storer B Patriarca F et al Longterm followup comparison nonmyeloablative allografting autografting newly diagnosed myeloma Blood 2011 117 67216727 59 Knop S Liebisch P Meisner C et al Autologous followed allogeneic versus tandemautologous stem cell transplant newly diagnosed FISHdel13q myeloma Blood 2014 124 143 60 Bruno B Rotta M Patriarca F et al A comparison allografting autografting newly diagnosed myeloma N Engl J Med 2007 356 11101120 61 Gahrton G Iacobelli S Björkstrand B et al Autologous reducedintensity allogeneic stem cell transplantation versus autologous transplantation multiple myeloma long term results EBMTNMAM2000 study Autologous reducedintensity allogeneic stem cell transplantation versus autologous Blood 2013 121 50555064 62 Krishnan A Pasquini MC Logan B et al Autologous haemopoietic stemcell transplantation followed allogeneic autologous haemopoietic stemcell transplantation patients multiple myeloma BMT CTN 0102 phase 3 biological assignment trial Lancet Oncol 2011 12 11951203 63 Lokhorst HM van der Holt B Cornelissen JJ et al Donor versus donor comparison newly diagnosed myeloma patients included HOVON 50 multiple myeloma study Blood 2012 119 62196225 64 Lokhorst HM van der Holt B Cornelissen JJ et al Reduced relapse rate upfront tandem autologousreduced intensity allogeneic transplantation multiple myeloma results borderline nonsignificant prolongation progression free overall survival Haematologica 2015 100 e508e510 65 Lokhorst HM Segeren CM Verdonck LF et al Partially Tcelldepleted allogeneic stem cell transplantation firstline treatment multiple myeloma prospective evaluation patients treated phase III study HOVON 24 MM J Clin Oncol 2003 21 17281733 66 Moreau P Garban F Attal M et al Long term followup results IFM9903 IFM9904 trials comparing nonmyeloablative allotransplantation autologous transplantation highrisk novo multiple myeloma Blood 2008 112 39143915 67 Björkstrand B Iacobelli S Hegenbart U et al Tandem autologousreducedintensity conditioning allogeneic stemcell transplantation versus autologous transplantation myeloma longterm followup J Clin Oncol 2011 29 30163022 68 Rosiñol L PérezSimón JA Sureda A et al A prospective PETHEMA study tandem autologous transplantation versus autograft followed reducedintensity conditioning allogeneic transplantation newly diagnosed multiple myeloma Blood 2008 112 3591 3593 69 Garban F Attal M Michallet M et al Prospective comparison autologous stem cell transplantation followed dosereduced allograft IFM9903 trial tandem autologous stem cell transplantation IFM9904 trial highrisk novo multiple myeloma Blood 2006 107 34743480 70 Greaves P Lister TA Gribben JG Parenthood longterm survivors CHOP etoposide treatment aggressive lymphomaresponse Meissner et al Br J Haematol 2014 166 615616 71 Kikuchi T Mori T Koda Y et al Outcome reducedintensity allogeneic hematopoietic stem cell transplantation multiple myeloma Int J Hematol 2015 102 670677 72 Hobo W Strobbe L Maas F et al Immunogenicity dendritic cells pulsed 14 journalssagepubcomhometah LE Franssen T Mutis et al MAGE3 Survivin Bcell maturation antigen mRNA vaccination multiple myeloma patients Cancer Immunol Immunother 2013 62 13811392 donor lymphocyte infusions patients multiple myeloma allogeneic stem cell transplantation Biol Blood Marrow Transplant 2018 24 13991405 73 Plesner T Arkenau HT Gimsing P et al 83 Vallet S Pecherstorfer M Podar K Phase 12 study daratumumab lenalidomide dexamethasone relapsed multiple myeloma Blood 2016 128 18211829 74 Bringhen S Gay F Pautasso C et al Evaluation pharmacokinetics preclinical clinical efficacy lenalidomide treatment multiple myeloma Expert Opin Drug Metab Toxicol 2012 8 12091222 75 van Donk NW van der Holt B Minnema MC et al Thalidomide autologous stem cell transplantation recently diagnosed multiple myeloma HOVON50 longterm results phase 3 randomised controlled trial Lancet Haematol 2018 5 e479e492 76 Kröger N Badbaran A Zabelina T et al Impact highrisk cytogenetics achievement molecular remission long term freedom disease autologous allogeneic tandem transplantation patients multiple myeloma Biol Blood Marrow Transplant 2013 19 398404 77 Moreau P San Miguel J Ludwig H et al Multiple myeloma ESMO clinical practice guidelines diagnosis treatment followup Ann Oncol 2013 24Suppl 6 vi133vi137 78 Giralt S Garderet L Durie B et al American Society Blood Marrow Transplant European Society Blood Marrow Transplantation Blood Marrow Transplant Clinical Trials Network International Myeloma Working Group Consensus Conference Salvage Hematopoietic Cell Transplan Biol Blood Marrow Transplant 2015 21 12 20392051 79 Palumbo A AvetLoiseau H Oliva S et al Revised international staging multiple myeloma report international myeloma working group J Clin Oncol 2015 33 28632869 80 Rajkumar SV Multiple myeloma 2013 update diagnosis riskstratification management Am J Hematol 2013 88 226235 81 Chu J He S Deng Y et al Genetic modification T cells redirected CS1 enhances eradication myeloma cells Clin Cancer Res 2014 20 39894000 82 Gröger M Gagelmann N Wolschke C et al Longterm results prophylactic Adoptive cell therapy multiple Myeloma Expert Opin Biol Ther 2017 17 15111522 84 Sarkar S van Gelder M Noort W et al Optimal selection natural killer cells kill myeloma role HLAE NKG2A Cancer Immunol Immunother 2015 64 951963 85 van Donk NWCJ Kröger N Hegenbart U et al Prognostic factors donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation multiple myeloma Bone Marrow Transplant 2006 37 11351141 86 Gorgun G Van De Donk G Groen RW et al Lenalidomide treatment relapsed refractory multiple myeloma Cancer Manag Res 2012 4 253268 87 Krönke J Udeshi ND Narla A et al Lenalidomide causes selective degradation IKZF1 IKZF3 multiple myeloma cells Science 2014 343 301305 88 LopezGirona A Mendy D Ito T et al Cereblon direct protein target immunomodulatory antiproliferative activities lenalidomide pomalidomide Leukemia 2012 26 23262335 89 Lu G Middleton RE Sun H et al The myeloma drug lenalidomide promotes cereblondependent destruction Ikaros proteins Science 2014 343 305309 90 Ito T Ando H Suzuki T et al Identification primary target thalidomide teratogenicity Science 2010 327 13451350 91 Avitahl N Winandy S Friedrich C et al Ikaros sets thresholds T cell activation regulates chromosome propagation Immunity 1999 10 333343 92 Clambey ET Collins B Young MH et al The Ikaros transcription factor regulates responsiveness IL12 expression IL2 receptor alpha mature activated CD8 T cells PLoS One 2013 8 110 93 Sehgal K Das R Zhang L et al Clinical pharmacodynamic analysis pomalidomide dosing strategies myeloma impact immune activation cereblon targets Blood 2015 125 40424051 94 Gandhi AK Kang J Havens CG et al Immunomodulatory agents lenalidomide pomalidomide costimulate T cells inducing journalssagepubcomhometah 15 Therapeutic Advances Hematology 10 degradation T cell repressors Ikaros Aiolos modulation E3 ubiquitin ligase complex CRL4CRBN Br J Haematol 2014 164 811821 95 Hagner PR Chiu H Ortiz M et al Activity lenalidomide mantle cell lymphoma explained NK cellmediated cytotoxicity Br J Haematol 2017 179 399409 96 Wu L Adams M Carter T et al Lenalidomide enhances natural killer cell monocyte mediated antibodydependent cellular cytotoxicity rituximabtreated CD20 tumor cells Clin Cancer Res 2008 14 46504657 97 Costa F Vescovini R Bolzoni M et al Lenalidomide increases human dendritic cell maturation multiple myeloma patients targeting monocyte differentiation modulating mesenchymal stromal cell inhibitory properties Oncotarget 2017 8 5305353067 98 Vo MC AnhNguyenThi T Lee HJ et al Lenalidomide enhances function dendritic cells generated patients multiple myeloma Exp Hematol 2017 46 4855 99 Holstein SA McCarthy PL Immunomodulatory drugs multiple myeloma mechanisms action clinical experience Drugs 2017 77 505520 100 Weber DM Chen C Niesvizky R et al Lenalidomide plus dexamethasone relapsed multiple myeloma North America N Engl J Med 2007 357 21332142 101 Dimopoulos M Spencer A Attal M et al Lenalidomide plus dexamethasone relapsed refractory multiple myeloma N Engl J Med 2007 357 21232132 102 Lacy MQ Hayman SR Gertz MA et al Pomalidomide CC4047 plus low dose dexamethasone Pomdex active tolerated lenalidomide refractory multiple myeloma MM Leukemia 2010 24 19341939 103 McCarthy PL Holstein SA Petrucci MT et al Lenalidomide maintenance autologous stemcell transplantation newly diagnosed multiple myeloma metaanalysis J Clin Oncol 2017 35 32793289 104 Maloney DG AntiCD20 antibody therapy Bcell lymphomas N Engl J Med 2012 366 20082016 105 Zonder JA Mohrbacher AF Singhal S et al A phase 1 multicenter openlabel dose escalation study elotuzumab patients advanced multiple myeloma Blood 2012 120 552559 106 Balasa B Yun R Belmar NA et al Elotuzumab enhances natural killer cell activation myeloma cell killing interleukin2 TNFα pathways Cancer Immunol Immunother 2015 64 6173 107 Lonial S Dimopoulos M Palumbo A et al Elotuzumab therapy relapsed refractory multiple myeloma N Engl J Med 2015 373 621631 108 Dimopoulos MA Lonial S White D et al Elotuzumab plus lenalidomidedexamethasone relapsed refractory multiple myeloma ELOQUENT2 followup posthoc analyses progressionfree survival tumour growth Br J Haematol 2017 178 896905 109 Jakubowiak A Offidani M Pégourie B et al Randomized phase 2 study elotuzumab plus bortezomibdexamethasone vs bortezomib dexamethasone relapsedrefractory MM Blood 2016 127 28332840 110 van Donk NWCJ Richardson PG Malavasi F CD38 antibodies multiple myeloma future Blood 2018 131 1329 111 Lonial S Weiss BM Usmani SZ et al Daratumumab monotherapy patients treatmentrefractory multiple myeloma SIRIUS openlabel randomised phase 2 trial Lancet 2016 387 15511560 112 Lokhorst HM Plesner T Laubach JP et al Targeting CD38 daratumumab monotherapy multiple myeloma N Engl J Med 2015 373 12071219 113 Usmani SZ Weiss BM Plesner T et al Clinical efficacy daratumumab monotherapy patients heavily pretreated relapsed refractory multiple myeloma Blood 2016 128 3744 114 Raab MS Chatterjee M Goldschmidt H et al MOR202 combination pomalidomide lenalidomide relapsed refractory multiple myeloma data clinically relevant cohorts phase IIIa study J Clin Oncol 2016 34 80128012 115 Vij R Lendvai N Martin TG et al A phase Ib dose escalation trial isatuximab SAR650984 antiCD38 mAb plus lenalidomide dexamethasone LenDex relapsedrefractory multiple myeloma RRMM interim results new dose cohorts J Clin Oncol 2016 34Suppl abstract 8009 116 Dimopoulos MA Oriol A Nahi H et al Daratumumab lenalidomide 16 journalssagepubcomhometah LE Franssen T Mutis et al dexamethasone multiple myeloma N Engl J Med 2016 375 13191331 117 Palumbo A ChananKhan A Weisel K et al Daratumumab bortezomib dexamethasone multiple myeloma N Engl J Med 2016 375 754766 118 Chari A Suvannasankha A Fay JW et al Daratumumab plus pomalidomide dexamethasone relapsed andor refractory multiple myeloma Blood 2017 130 974981 119 Mateos MV Dimopoulos MA Cavo M et al Daratumumab plus bortezomib melphalan prednisone untreated myeloma N Engl J Med 2018 378 518528 120 Tai YT Mayes PA Acharya C et al Novel antiBcell maturation antigen antibodydrug conjugate GSK2857916 selectively induces killing multiple myeloma Blood 2014 123 31283138 121 Trudel S Lendvai N Popat R et al Deep durable responses patients Pts Relapsedrefractory multiple myeloma MM treated monotherapy GSK2857916 antibody drug conjugate Bcell maturation antigen BCMA preliminary results 2 study BMA117159 Blood 2017 130Suppl 1 741 122 June CH Sadelain M Chimeric antigen receptor therapy N Engl J Med 2018 379 6473 123 Kochenderfer JN Dudley ME Kassim SH et al Chemotherapyrefractory diffuse large Bcell lymphoma indolent Bcell malignancies effectively treated autologous T cells expressing antiCD19 chimeric antigen receptor J Clin Oncol 2015 33 540549 124 Maude SL Frey N Shaw PA et al Chimeric antigen receptor T cells sustained remissions leukemia N Engl J Med 2014 371 1507 1517 125 Brudno J Lam N Wang M et al Tcells genetically modified express antiB cell maturation antigen chimeric antigen receptor CD28 costimulatory moiety cause remissions poorprognosis relapsed multiple myeloma J Clin Oncol 2018 36 22672280 126 Berdeja JG Lin Y Raje N et al Durable clinical responses heavily pretreated patients relapsedrefractory multiple myeloma updated results multicenter study bb2121 antiBcma CAR T Cell Therapy Blood 2017 130Suppl 1 740 127 Cohen AD Garfall AL Stadtmauer EA et al Safety efficacy Bcell maturation antigen BCMAspecific chimeric antigen receptor T cells CARTBCMA cyclophosphamide conditioning refractory multiple myeloma MM Blood 2017 130 505 128 Ali SA Shi V Maric I et al T cells expressing antiBcell maturation antigen chimeric antigen receptor cause remissions multiple myeloma Blood 2016 128 1688700 129 Raje N Jesus B Lin Y et al bb2121 anti BCMA CAR Tcell therapy patients relapsedrefractory multiple myeloma updated results multicenter phase I study J Clin Oncol 2018 36Suppl abstract 8007 130 Zhang W Zhao W Liu J et al Phase I open label trial antiBCMA chimeric antigen receptor T cells patients relapsed refractory multiple myeloma EHA Abstr 2017 abstract S103 131 Smith EL Mailankody S Ghosh A et al Development evaluation human single chain variable fragment scFv Derived Bcma targeted CAR T cell vector leads high objective response rate patients advanced MM Blood 2017 130Suppl 1 742 132 Ramos CA Savoldo B Torrano V et al Clinical responses T lymphocytes targeting malignancyassociated κ light chains J Clin Invest 2016 126 25882596 133 Drent E Poels R Mulders MJ et al Feasibility controlling CD38CAR T cell activity Teton inducible CAR design PLoS One 2018 13 e0197349 134 Drent E Groen RWJ Noort WA et al Pre clinical evaluation CD38 chimeric antigen receptor engineered T cells treatment multiple myeloma Haematologica 2016101 616625 135 Gogishvili T Danhof S Prommersberger S et al SLAMF7CAR T cells eliminate myeloma confer selective fratricide SLAMF7 normal lymphocytes Blood 2017 130 28382847 136 Thakur A Huang M Lum LG Bispecific antibody based therapeutics strengths challenges Blood Rev 2018 32 339347 137 Topp MS Gökbuget N Stein AS et al Safety activity blinatumomab adult patients relapsed refractory Bprecursor acute lymphoblastic leukaemia multicentre singlearm phase 2 study Lancet Oncol 2015 16 5766 journalssagepubcomhometah 17 Therapeutic Advances Hematology 10 138 Kantarjian H Stein A Gökbuget N et al Blinatumomab versus chemotherapy advanced acute lymphoblastic leukemia N Engl J Med 2017 376 836847 139 Viardot A Goebeler ME Hess G et al Phase 2 study bispecific Tcell engager BiTE antibody blinatumomab relapsedrefractory diffuse large Bcell lymphoma Blood 2016 127 14101416 140 Goebeler ME Knop S Viardot A et al Bispecific Tcell engager BiTE antibody construct blinatumomab treatment patients relapsedrefractory nonhodgkin lymphoma final results phase I study J Clin Oncol 2016 34 11041111 141 Zou J Chen D Zong Y et al Immunotherapy based bispecific Tcell engager hIgG1 Fc sequence new therapeutic strategy multiple myeloma Cancer Sci 2015 106 512521 142 Carpenter RO Evbuomwan MO Pittaluga S et al Bcell maturation antigen promising target adoptive Tcell therapy multiple myeloma Clin Cancer Res 2013 19 20482060 143 Duell J Dittrich M Bedke T et al Frequency regulatory Tcells determines outcome Tcellengaging antibody blinatumomab patients Bprecursor ALL Leukemia 2017 31 21812190 144 Chen R Zinzani PL Fanale MA et al Phase II study efficacy safety pembrolizumab relapsedrefractory classic Hodgkin lymphoma J Clin Oncol 2017 35 21252132 145 Armand P Shipp MA Ribrag V et al Programmed death1 blockade pembrolizumab patients classical Hodgkin lymphoma brentuximab vedotin failure J Clin Oncol 2016 34 37333739 146 Paiva B Azpilikueta A Puig N et al PDL1 PD1 presence tumor microenvironment activity PD1 blockade multiple myeloma Leukemia 2015 29 21102113 147 Liu J Hamrouni A Wolowiec D et al Plasma cells multiple myeloma patients express B7H1 PDL1 increase expression stimulation IFNγ TLR ligands MyD88 TRAF6 MEKdependent pathway Blood 2007 110 296304 148 Lesokhin AM Ansell SM Armand P et al Nivolumab patients relapsed refractory hematologic malignancy preliminary results phase Ib study J Clin Oncol 2016 34 26982704 149 Ocio EM Mateos MV Orlowski RZ et al Pembrolizumab pembro plus lenalidomide len lowdose dexamethasone dex relapsedrefractory multiple myeloma RRMM efficacy biomarker analyses J Clin Oncol 2017 35 80158015 150 Badros A Hyjek E Ma N et al Pembrolizumab pomalidomide lowdose dexamethasone relapsedrefractory multiple myeloma Blood 2017 130 11891197 151 Bezman NA Jhatakia A Kearney AY et al PD1 blockade enhances elotuzumab efficacy mouse tumor models Blood Adv 2017 1 753765 152 Palucka K Banchereau J Cancer immunotherapy dendritic cells Nat Rev Cancer 2012 12 265277 153 Anguille S Smits EL Lion E et al Clinical use dendritic cells cancer therapy Lancet Oncol 2014 15 e257e267 154 Rosenblatt J Avivi I Vasir B et al Vaccination dendritic celltumor fusions following autologous stem cell transplant induces immunologic clinical responses multiple myeloma patients Clin Cancer Res 2013 1936403648 155 Rosenblatt J Vasir B Uhl L et al Vaccination dendritic celltumor fusion cells results cellular humoral antitumor immune responses patients multiple myeloma Blood 2011 117 393402 156 Hobo W Strobbe L Maas F et al Immunogenicity dendritic cells pulsed MAGE3 Survivin Bcell maturation antigen mRNA vaccination multiple myeloma patients Cancer Immunol Immunother 2013 62 13811392 157 Hoang MD Jung SH Lee HJ et al Dendritic cellbased cancer immunotherapy multiple myeloma bench clinic Chonnam Med J 2015 51 17 158 Shlomchik WD Couzens MS Tang CB et al Prevention graft versus host disease inactivation host antigenpresenting cells Science 1999 285 412415 159 Mapara MY Kim YM Wang SP et al Donor lymphocyte infusions mediate superior graft versusleukemia effects mixed compared fully allogeneic chimeras critical role host antigenpresenting cells Blood 2002 100 19031909 160 Sykes M Sheard MA Sachs DH Graft versushostrelated immunosuppression induced mixed chimeras 18 journalssagepubcomhometah LE Franssen T Mutis et al alloresponses host donor lymphohematopoietic cells J Exp Med 1988 16823912396 161 AuffermannGretzinger S Lossos IS Vayntrub TA et al Rapid establishment dendritic cell chimerism allogeneic hematopoietic cell transplant recipients Blood 2002 99 14421448 162 Oostvogels R Kneppers E Minnema MC et al Efficacy hostdendritic cell vaccinations minor histocompatibility antigen loading combined donor lymphocyte infusion multiple myeloma patients Bone Marrow Transplant 2017 52 228237 163 Franssen LE Roeven MWH Hobo W et al A phase III minor histocompatibility antigen loaded dendritic cell vaccination trial safely improve efficacy donor lymphocyte infusions myeloma Bone Marrow Transplant 2017 52 13781383 Visit SAGE journals online journalssagepubcom hometah SAGE journals journalssagepubcomhometah 19